XML 71 R54.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Aug. 31, 2020
Mar. 31, 2020
Aug. 31, 2018
May 31, 2018
Sep. 30, 2020
Mar. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2016
Other Commitments [Line Items]                    
Gain (loss) on strategic investment             $ (997) $ 997 $ (1,840)  
Restricted cash             5,770 4,787 4,826  
Corporate Credit Card Program | Letter of Credit                    
Other Commitments [Line Items]                    
Restricted cash                   $ 2,000
Fleet Program | Letter of Credit                    
Other Commitments [Line Items]                    
Restricted cash             400      
Other assets                    
Other Commitments [Line Items]                    
Aggregate carrying amount of strategic equity investment             1,300 2,300    
Other expense                    
Other Commitments [Line Items]                    
Gain (loss) on strategic investment             (1,000) 1,000    
Cersci Therapeutics                    
Other Commitments [Line Items]                    
Upfront consideration and transaction costs $ 52,800                  
Upfront payment $ 44,300                  
Upfront payment conditions The Company incurred an aggregate of $52.8 million in upfront consideration and transaction costs, of which, $44.3 million was paid through the issuance of approximately 1.2 million shares of the Company’s common stock.                  
Common stock issuance 1,200,000                  
Cersci Therapeutics | Research and development                    
Other Commitments [Line Items]                    
Assets acquisition and upfront payment         $ 45,700          
License Agreements                    
Other Commitments [Line Items]                    
Upfront payment             $ 72,700 $ 1,400 10,000  
License Agreements | Neuren | North America                    
Other Commitments [Line Items]                    
Upfront payment   $ 10,000                
Upfront license fee     $ 10,000              
License Agreements | Neuren | Research and development | North America                    
Other Commitments [Line Items]                    
Upfront payment           $ 10,000     $ 10,000  
Exclusivity Deed | Neuren                    
Other Commitments [Line Items]                    
Aggregate carrying amount of strategic equity investment       $ 3,100            
Shares subscribed       1,330,000            
Exclusivity Deed | Neuren | Sales, general and administrative                    
Other Commitments [Line Items]                    
Payments for exclusive right       $ 900            
Maximum                    
Other Commitments [Line Items]                    
Percentage of royalty payments obligation on net product sales             2.00%      
Mile stone payments payable             $ 2,200,000      
Maximum | Cersci Therapeutics | Development Commercialization and Sales Milestones                    
Other Commitments [Line Items]                    
Compensation expense related to mergers to former holders $ 887,000                  
Maximum | License Agreements | Neuren | North America                    
Other Commitments [Line Items]                    
Mile stone payments payable   $ 515,000 $ 455,000     $ 515,000